Universität zu Köln

Thangarajah, Fabinshy, Eichler, Christian, Fromme, Julia, Malter, Wolfram, Radosa, Julia Caroline, Ludwig, Sebastian, Puppe, Julian, Paepke, Stefan and Warm, Matthias (2019). The impact of EndoPredict((R))on decision making with increasing oncological work experience: can overtreatment be avoided? Arch. Gynecol. Obstet., 299 (5). S. 1437 - 1443. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-0711

Full text not available from this repository.

Abstract

BackgroundEstimating distant recurrence risk in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer is still challenging. EndoPredict((R)) is a gene expression-based test predicting the likelihood of recurrent disease. We analyzed the difference in oncological decision making with and without the knowledge of gene expression tests.Patients and methodsThis is a retrospective analysis including patients diagnosed with hormone-receptor positive, Her2 negative breast cancer between 2011 and 2015 at the Municipal Breast Cancer Centre Cologne, Germany. All patients received an evaluation by EndoPredict((R)). An oncological tumor board (TB) with knowledge of these results served as a baseline (control group). This baseline was compared to the treatment decision (adjuvant chemotherapy yes vs. no) made by oncologists with different experience levels (less than 5years, between 5 and 15years, and more than 15years) who were not provided the EndoPredict((R)) scores. All clinicians had access to clinical as well to histopathological data.ResultsThere was no significant difference between control group and the oncologists with different experience levels concerning a chemotherapy indication. A trend could be shown in the subgroup of nodal negative patients between the treatment recommendation and physicians with more than 15years of experience (p=0.088). A further trend could be demonstrated in the subgroup of patients with a low Ki67 index (14%) (p=0.063) between physician with 5-10years of clinical experience and official treatment recommendation.ConclusionIt seems that inexperienced physicians may profit from the use of EndoPredict((R)) to avoid an overtreatment. In nodal negative patients and patients with a low Ki67 index, undertreatment can be avoided with the use of EndoPredict((R)) (borderline significance). Further prospective studies with larger study cohorts are needed to further validate this tool.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Thangarajah, Fabinshy UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichler, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Fromme, Julia UNSPECIFIED UNSPECIFIED UNSPECIFIED Malter, Wolfram UNSPECIFIED UNSPECIFIED UNSPECIFIED Radosa, Julia Caroline UNSPECIFIED UNSPECIFIED UNSPECIFIED Ludwig, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Puppe, Julian UNSPECIFIED UNSPECIFIED UNSPECIFIED Paepke, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Warm, Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-149410
DOI:	10.1007/s00404-019-05097-w
Journal or Publication Title:	Arch. Gynecol. Obstet.
Volume:	299
Number:	5
Page Range:	S. 1437 - 1443
Date:	2019
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-0711
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language BREAST; RECOMMENDATIONS; CHEMOTHERAPY; INFORMATION; RECURRENCE; SCORE; RISK Multiple languages Obstetrics & Gynecology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14941